STT3A

Across TCGA pan-cancer cohorts, STT3A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STT3A data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher STT3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STT3A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LIHC, and LUSC are the cancer types where STT3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.010	0.768	<.001	30	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.205	0.631	.017	12	view →
UCEC	DFS	Median	All	0.835	0.631	.023	6	view →
SKCM	DFS	Median	II,III,IV	0.219	0.711	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STT3A–HNSC (OS)

Open the HNSC breakdown →